Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$50,000.00
What the client paid this registrant for the period.
Client based in
Maryland

Official filing document

 Lobbyists on this filing 4
  • LAURA M SIMMONS
    Previously held: Advisor, Office of Legislative Affairs, Dept of Homeland Security
  • CHRISTOPHER E. WILCOX
    Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
  • JEANNE HAGGERTY
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
  • ROBERT BUTORA
    Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 1
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 4
Medicare/Medicaid

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Health Issues

Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.

Taxation/Internal Revenue Code

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Trade (domestic/foreign)

Issues related to pharmaceutical tariffs and related trade agreements.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem